drugset / Trial / NCT07113392

A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension

NCT07113392

Phase 3 Not yet recruiting 144 enrolled Jiangxi Kvvit Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety, efficacy and pharmacokinetics of Suraxavir Marboxil compared with oseltamivir in Pediatric Patients (2 to \<12 Years) with Uncomplicated Influenza.

Timeline

Start
2025-08-01
Primary completion
2026-08-01
Completion
2026-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oseltamivir Small molecule 30 mg Oral
Comparator Oseltamivir Small molecule 45 mg Oral
Comparator Oseltamivir Small molecule 60 mg Oral
Comparator Oseltamivir Small molecule 75 mg Oral
Subject Suraxavir marboxil Unknown 20 mg Oral
Subject Suraxavir marboxil Unknown 40 mg Oral

Indications